2980 related articles for article (PubMed ID: 30661105)
21. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function.
Morgan CJA; Freeman TP; Hindocha C; Schafer G; Gardner C; Curran HV
Transl Psychiatry; 2018 Sep; 8(1):181. PubMed ID: 30185793
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users.
Spindle TR; Cone EJ; Goffi E; Weerts EM; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
Drug Alcohol Depend; 2020 Jun; 211():107937. PubMed ID: 32247649
[TBL] [Abstract][Full Text] [Related]
23. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review.
Freeman AM; Petrilli K; Lees R; Hindocha C; Mokrysz C; Curran HV; Saunders R; Freeman TP
Neurosci Biobehav Rev; 2019 Dec; 107():696-712. PubMed ID: 31580839
[TBL] [Abstract][Full Text] [Related]
24. A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol.
Bergeria CL; Strickland JC; Spindle TR; Kalaba M; Satyavolu PU; Feldner M; Vandrey R; Bonn-Miller M; Peters EN; Weerts E
Exp Clin Psychopharmacol; 2023 Apr; 31(2):312-317. PubMed ID: 35467921
[TBL] [Abstract][Full Text] [Related]
25. Individual and combined effects of cannabidiol and Δ
Wall MB; Freeman TP; Hindocha C; Demetriou L; Ertl N; Freeman AM; Jones AP; Lawn W; Pope R; Mokrysz C; Solomons D; Statton B; Walker HR; Yamamori Y; Yang Z; Yim JL; Nutt DJ; Howes OD; Curran HV; Bloomfield MA
J Psychopharmacol; 2022 Jun; 36(6):732-744. PubMed ID: 35596578
[TBL] [Abstract][Full Text] [Related]
26. Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report.
Pichler EM; Kawohl W; Seifritz E; Roser P
Int J Psychiatry Med; 2019 Mar; 54(2):150-156. PubMed ID: 30058466
[TBL] [Abstract][Full Text] [Related]
27. Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.
Englund A; Oliver D; Chesney E; Chester L; Wilson J; Sovi S; De Micheli A; Hodsoll J; Fusar-Poli P; Strang J; Murray RM; Freeman TP; McGuire P
Neuropsychopharmacology; 2023 May; 48(6):869-876. PubMed ID: 36380220
[TBL] [Abstract][Full Text] [Related]
28. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.
Englund A; Morrison PD; Nottage J; Hague D; Kane F; Bonaccorso S; Stone JM; Reichenberg A; Brenneisen R; Holt D; Feilding A; Walker L; Murray RM; Kapur S
J Psychopharmacol; 2013 Jan; 27(1):19-27. PubMed ID: 23042808
[TBL] [Abstract][Full Text] [Related]
29. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.
Wade DT; Robson P; House H; Makela P; Aram J
Clin Rehabil; 2003 Feb; 17(1):21-9. PubMed ID: 12617376
[TBL] [Abstract][Full Text] [Related]
30. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
[TBL] [Abstract][Full Text] [Related]
31. Δ9-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption.
Stern CA; Gazarini L; Vanvossen AC; Zuardi AW; Galve-Roperh I; Guimaraes FS; Takahashi RN; Bertoglio LJ
Eur Neuropsychopharmacol; 2015 Jun; 25(6):958-65. PubMed ID: 25799920
[TBL] [Abstract][Full Text] [Related]
32. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment.
Lawn W; Trinci K; Mokrysz C; Borissova A; Ofori S; Petrilli K; Bloomfield M; Haniff ZR; Hall D; Fernandez-Vinson N; Wang S; Englund A; Chesney E; Wall MB; Freeman TP; Curran HV
Addiction; 2023 Jul; 118(7):1282-1294. PubMed ID: 36750134
[TBL] [Abstract][Full Text] [Related]
33. Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol.
Hollister LE; Gillespie H
Clin Pharmacol Ther; 1975 Jul; 18(1):80-3. PubMed ID: 1097148
[TBL] [Abstract][Full Text] [Related]
34. Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over study.
Oliver D; Englund A; Chesney E; Chester L; Wilson J; Sovi S; Wigroth S; Hodsoll J; Strang J; Murray RM; Freeman TP; Fusar-Poli P; McGuire P
Addiction; 2024 Feb; 119(2):322-333. PubMed ID: 37821096
[TBL] [Abstract][Full Text] [Related]
35. A Critical Review of the Role of the Cannabinoid Compounds Δ
Jones É; Vlachou S
Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
[TBL] [Abstract][Full Text] [Related]
36. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.
Morgan CJ; Freeman TP; Schafer GL; Curran HV
Neuropsychopharmacology; 2010 Aug; 35(9):1879-85. PubMed ID: 20428110
[TBL] [Abstract][Full Text] [Related]
37. An assessment of concurrent cannabidiol and Δ⁹-tetrahydrocannabinol administration in place aversion and taste avoidance conditioning.
Hempel BJ; Clasen MM; Nelson KH; Woloshchuk CJ; Riley AL
Exp Clin Psychopharmacol; 2018 Apr; 26(2):205-213. PubMed ID: 29648861
[TBL] [Abstract][Full Text] [Related]
38. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.
Fusar-Poli P; Crippa JA; Bhattacharyya S; Borgwardt SJ; Allen P; Martin-Santos R; Seal M; Surguladze SA; O'Carrol C; Atakan Z; Zuardi AW; McGuire PK
Arch Gen Psychiatry; 2009 Jan; 66(1):95-105. PubMed ID: 19124693
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
Bansal S; Zamarripa CA; Spindle TR; Weerts EM; Thummel KE; Vandrey R; Paine MF; Unadkat JD
Clin Pharmacol Ther; 2023 Sep; 114(3):693-703. PubMed ID: 37313955
[TBL] [Abstract][Full Text] [Related]
40. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]